ACE2 and acute respiratory distress syndrome: However, no improvement in clinical or physiological measures of ARDS were seen with the addition of exogenous ACE2 in patients with ARDS (Khan et al., 2017); however, these studies did not have the sufficient statistical power to identify potential clinical benefits.